The price of Ruxolitinib varies depending on the formulation, dosage, and whether insurance or patient assistance programs are utilized. For example, a 30-count bottle of 5 mg Ruxolitinib tablets can cost around $1,200 to $1,400. A 30-count bottle of 20 mg tablets may range from $3,800 to $4,000. These prices reflect retail costs and do not account for potential discounts or co-pays.
How much does a 30-day supply of Ruxolitinib cost?
A 30-day supply of Ruxolitinib can significantly impact out-of-pocket expenses. For instance, two bottles of 15 mg Ruxolitinib tablets, each containing 30 count, might cost approximately $7,600. The exact cost is influenced by pharmacy pricing and any applicable insurance coverage or patient support.
Are there ways to reduce the cost of Ruxolitinib?
Several avenues exist for reducing Ruxolitinib costs. Pharmaceutical companies often offer patient assistance programs for eligible individuals who meet certain financial criteria. Additionally, coupons and discount cards from manufacturers or third-party providers can lower the immediate cost at the pharmacy. Comparing prices across different pharmacies can also yield savings.
What is the difference between Jakafi and Ruxolitinib?
Jakafi is the brand name for Ruxolitinib. Therefore, there is no therapeutic difference; Jakafi is the branded version of the generic drug Ruxolitinib [1].
When does the patent for Ruxolitinib expire?
The patent landscape for Ruxolitinib is complex and involves multiple patents covering the drug substance, its manufacturing processes, and methods of use. For instance, certain patents related to Ruxolitinib are listed in the U.S. Food and Drug Administration's (FDA) Orange Book, indicating their relevance to exclusivity and potential generic competition [2]. Specific patent expiry dates can be found through resources that track pharmaceutical intellectual property, such as DrugPatentWatch.com [3].
Can generic versions of Ruxolitinib be available before patent expiry?
Generally, generic versions of a drug cannot be marketed until the relevant patents expire or are successfully challenged. The Hatch-Waxman Act provides a framework for generic drug approval, but patent challenges and exclusivities can extend market protection for the innovator drug. Information on specific patent litigation and the status of generic Ruxolitinib availability can be found by consulting patent databases and legal analyses [3].
Who manufactures Ruxolitinib?
Ruxolitinib is manufactured by Incyte Corporation and marketed under the brand name Jakafi. It is also available in some markets as a generic [1].
What clinical trials have been conducted for Ruxolitinib?
Ruxolitinib has been evaluated in numerous clinical trials for various myeloproliferative neoplasms and other conditions. These trials have investigated its efficacy and safety in treating conditions like myelofibrosis, polycythemia vera, and graft-versus-host disease [4].
What are the approved uses for Ruxolitinib?
Ruxolitinib (Jakafi) is approved by the FDA for treating intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis [4]. It is also approved for polycythemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea [4]. Additionally, it is indicated for steroid-refractory acute graft-versus-host disease and chronic graft-versus-host disease after failure of at least one systemic therapy [4].
What are the side effects associated with Ruxolitinib?
Common side effects of Ruxolitinib include low blood cell counts (anemia, thrombocytopenia, neutropenia), diarrhea, muscle spasms, weight gain, and headache [4]. More serious side effects can include serious infections, an increased risk of certain cancers, and cardiac events [4]. Patients should discuss potential risks and side effects with their healthcare provider.
---
Sources:
[1] National Institutes of Health. (n.d.). Ruxolitinib. U.S. National Library of Medicine. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Ruxolitinib
[2] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvalsand-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
[3] DrugPatentWatch.com. (n.d.). Ruxolitinib Patents. Retrieved from https://drugpatentwatch.com/
[4] Incyte Corporation. (2023). Jakafi Prescribing Information. Retrieved from https://www.incyte.com/products/jakafi